Risk assessment will encompass the twelve modifiable risk factors identified by The Lancet Commission in 2020 [14], apolipoprotein E (APOE) genotyping, and assessment of biological indicators of brain disease such as brain beta-amyloid, brain tauopathy, neurodegeneration, and cerebrovascular disease. Here, APOE is linked to cerebrovascular disorder.